These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 4738278

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C, Ardiet C, Bret M, Laville M, Fiere D, Tranchand B, Fouque D.
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S.
    Cancer; 2004 Jun 15; 100(12):2607-12. PubMed ID: 15197803
    [Abstract] [Full Text] [Related]

  • 8. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A, Lokeshwar N, Raina V, Mohanti BK, Kumar R.
    Natl Med J India; 2007 Jun 15; 20(3):121-4. PubMed ID: 17867615
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
    Colović MD, Janković GM, Nikolov VS, Suvajdzić ND, Miletić VD.
    Haematologia (Budap); 1994 Jun 15; 26(2):91-6. PubMed ID: 7890267
    [Abstract] [Full Text] [Related]

  • 14. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, Singer C, Harding S, Foot N, Hallam S, Odeh L, Joel S, Cavenagh J.
    Br J Haematol; 2009 Mar 15; 144(6):887-94. PubMed ID: 19183191
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
    Fenk R, Schneider P, Kropff M, Huenerlituerkoglu AN, Steidl U, Aul C, Hildebrandt B, Haas R, Heyll A, Kobbe G, West German Myeloma Study Group.
    Br J Haematol; 2005 Aug 15; 130(4):588-94. PubMed ID: 16098074
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Multiple myeloma. Prolonged periods of remission can be produced in myelomatosis with alkylating agents.
    Leone LA, Albala MM.
    R I Med J; 1965 Sep 15; 48(9):478-85. PubMed ID: 5213242
    [No Abstract] [Full Text] [Related]

  • 20. [Clinical contribution the the therapy of multiple myeloma with phenylalanine mustard (melphalan)].
    Giardin A, Del Mela P, Morandi GA.
    Riv Crit Clin Med; 1966 Aug 15; 66(3):244-54. PubMed ID: 6002407
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.